Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia

J Pediatr Hematol Oncol. 2018 May;40(4):331-333. doi: 10.1097/MPH.0000000000000934.

Abstract

The prognosis of relapsed Wilms tumor (WT) with diffuse anaplasia is dismal, therefore, novel therapeutic strategies need to be explored. We reported on 2 consecutive cases with relapsed anaplastic WT who presented a partial response after 2 courses of vincristine, irinotecan, and bevacizumab association. This regimen may have a role in the treatment of patients with anaplastic advanced WT.

Publication types

  • Case Reports

MeSH terms

  • Anaplasia
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bevacizumab / administration & dosage
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Irinotecan / administration & dosage
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Male
  • Vincristine / administration & dosage
  • Wilms Tumor / drug therapy*
  • Wilms Tumor / pathology

Substances

  • Bevacizumab
  • Vincristine
  • Irinotecan